AI Transforming Care for CNS Autoimmune Disorders
Exploring the use of AI technologies in improving diagnosis and management of CNS autoimmune diseases.
Exploring the use of AI technologies in improving diagnosis and management of CNS autoimmune diseases.
Argenx's Phase 3 trial of VYVGART shows significant promise in treating autoimmune myositis, marking a milestone in the company's journey.
Recent data suggests a moderate rise in autoimmune disease risk with estrogen-only therapy, prompting further discussions on hormone treatment.
A recent study reveals that most people with GFAP astrocytopathy are misdiagnosed, leading to delays in treatment.
Verily Health and Autoimmune Registry Inc. have partnered to bolster research on autoimmune diseases by leveraging their combined expertise.
Research reveals how minor genetic alterations in immune cells can lead to autoimmune diseases and their connection to blood cancer.
A large study reveals how hormone therapy formulations affect autoimmune disease risk in menopausal women.
Argenx reveals Phase 3 ALKIVIA study findings showing efgartigimod's effectiveness in autoimmune myositis.
New research highlights significant delays and misdiagnoses faced by women with autoimmune diseases compared to men.
Women often experience longer wait times for accurate autoimmune disease diagnoses due to various factors.
A woman's years of muscle weakness culminate in a critical diagnosis after swallowing difficulties arise.
A new study shows a concerning trend where many women with autoimmune disorders are misdiagnosed with mental health issues.